Safe engineering of CAR T cells for adoptive cell therapy of cancer using long-term episomal gene transfer

EMBO Molecular Medicine

Volumn 8, Issue 7, 2016, Pages 702-711

  Jin, Chuan ^a   Fotaki, Grammatiki ^a   Ramachandran, Mohanraj ^a   Nilsson, Berith ^a   Essand, Magnus ^a   Yu, Di ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

CAR T cells; episomal cell engineering; non integrating lentivirus (NILV); scaffold matrix attachment region (S MAR) element; self replicating DNA

Indexed keywords

CD19 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; GAMMA INTERFERON; GREEN FLUORESCENT PROTEIN; LENTIVIRUS VECTOR; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; NON INTEGRATING LENTIVIRUS VECTOR; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CAR GENE; CELL DIVISION; CELL ENGINEERING; CELL THERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DOWN REGULATION; EMBRYO; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; GENE TARGETING; GENE TRANSFER; GFP GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LONG TERM EPISOMAL GENE TRANSFER; MATRIX ATTACHMENT REGION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA INTERFERENCE; T LYMPHOCYTE; TRANSGENE;

EID: 85027937461     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.15252/emmm.201505869     Document Type: Article

References (33)

1. Apolonia L, Waddington SN, Fernandes C, Ward NJ, Bouma G, Blundell MP, Thrasher AJ, Collins MK, Philpott NJ (2007) Stable gene transfer to muscle using non-integrating lentiviral vectors. Mol Ther 15: 1947–1954
2. Avedillo Diez I, Zychlinski D, Coci EG, Galla M, Modlich U, Dewey RA, Schwarzer A, Maetzig T, Mpofu N, Jaeckel E et al (2011) Development of novel efficient SIN vectors with improved safety features for Wiskott-Aldrich syndrome stem cell based gene therapy. Mol Pharm 8: 1525–1537
3. Barrett DM, Liu X, Jiang S, June CH, Grupp SA, Zhao Y (2013) Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia. Hum Gene Ther 24: 717–727
4. Baum C, Dullmann J, Li Z, Fehse B, Meyer J, Williams DA, von Kalle C (2003) Side effects of retroviral gene transfer into hematopoietic stem cells. Blood 101: 2099–2114
5. Bode J, Kohwi Y, Dickinson L, Joh T, Klehr D, Mielke C, Kohwi-Shigematsu T (1992) Biological significance of unwinding capability of nuclear matrix-associating DNAs. Science 255: 195–197
6. Butler SL, Hansen MS, Bushman FD (2001) A quantitative assay for HIV DNA integration in vivo. Nat Med 7: 631–634
7. Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska M et al (2014) Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 6: 224ra225
8. Farnet CM, Haseltine WA (1991) Circularization of human immunodeficiency virus type 1 DNA in vitro. J Virol 65: 6942–6952
9. Fu Y, Foden JA, Khayter C, Maeder ML, Reyon D, Joung JK, Sander JD (2013) High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol 31: 822–826
10. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF et al (2013) Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368: 1509–1518
11. Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A, Morillon E, Clappier E, Caccavelli L, Delabesse E, Beldjord K et al (2008) Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 118: 3132–3142
12. Iwakuma T, Cui Y, Chang LJ (1999) Self-inactivating lentiviral vectors with U3 and U5 modifications. Virology 261: 120–132
13. Jackson DA, Juranek S, Lipps HJ (2006) Designing nonviral vectors for efficient gene transfer and long-term gene expression. Mol Ther 14: 613–626
14. Jenke BH, Fetzer CP, Stehle IM, Jonsson F, Fackelmayer FO, Conradt H, Bode J, Lipps HJ (2002) An episomally replicating vector binds to the nuclear matrix protein SAF-A in vivo. EMBO Rep 3: 349–354
15. Jenke AC, Scinteie MF, Stehle IM, Lipps HJ (2004a) Expression of a transgene encoded on a non-viral episomal vector is not subject to epigenetic silencing by cytosine methylation. Mol Biol Rep 31: 85–90
16. Jenke AC, Stehle IM, Herrmann F, Eisenberger T, Baiker A, Bode J, Fackelmayer FO, Lipps HJ (2004b) Nuclear scaffold/matrix attached region modules linked to a transcription unit are sufficient for replication and maintenance of a mammalian episome. Proc Natl Acad Sci USA 101: 11322–11327
17. Jin C, Yu D, Hillerdal V, Wallgren A, Karlsson-Parra A, Essand M (2014) Allogeneic lymphocyte-licensed DCs expand T cells with improved antitumor activity and resistance to oxidative stress and immunosuppressive factors. Mol Ther Methods Clin Dev 1: 14001
18. Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, White DE, Wunderlich JR, Canevari S, Rogers-Freezer L et al (2006) A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 12: 6106–6115
19. Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, Yang JC, Phan GQ, Hughes MS, Sherry RM et al (2015) Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 33: 540–549
20. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN et al (2015) T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385: 517–528
21. Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, Rossig C, Russell HV, Diouf O, Liu E et al (2011) Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118: 6050–6056
22. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF et al (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371: 1507–1517
23. Mielke C, Kohwi Y, Kohwi-Shigematsu T, Bode J (1990) Hierarchical binding of DNA fragments derived from scaffold-attached regions: correlation of properties in vitro and function in vivo. Biochemistry 29: 7475–7485
24. Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D, Samanta M, Lakhal M, Gloss B, Danet-Desnoyers G et al (2009) Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 17: 1453–1464
25. Modlich U, Navarro S, Zychlinski D, Maetzig T, Knoess S, Brugman MH, Schambach A, Charrier S, Galy A, Thrasher AJ et al (2009) Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther 17: 1919–1928
26. Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U, Glimm H, Kuhlcke K, Schilz A, Kunkel H et al (2006) Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 12: 401–409
27. Piechaczek C, Fetzer C, Baiker A, Bode J, Lipps HJ (1999) A vector based on the SV40 origin of replication and chromosomal S/MARs replicates episomally in CHO cells. Nucleic Acids Res 27: 426–428
28. Schmidt M, Schwarzwaelder K, Bartholomae C, Zaoui K, Ball C, Pilz I, Braun S, Glimm H, von Kalle C (2007) High-resolution insertion-site analysis by linear amplification-mediated PCR (LAM-PCR). Nat Methods 4: 1051–1057
29. Verghese SC, Goloviznina NA, Skinner AM, Lipps HJ, Kurre P (2014) S/MAR sequence confers long-term mitotic stability on non-integrating lentiviral vector episomes without selection. Nucleic Acids Res 42: e53
30. Voigtlander R, Haase R, Muck-Hausl M, Zhang W, Boehme P, Lipps HJ, Schulz E, Baiker A, Ehrhardt A (2013) A novel adenoviral hybrid-vector system carrying a plasmid replicon for safe and efficient cell and gene therapeutic applications. Mol Ther Nucleic Acids 2: e83
31. Weibrecht I, Gavrilovic M, Lindbom L, Landegren U, Wahlby C, Soderberg O (2012) Visualising individual sequence-specific protein-DNA interactions in situ. N Biotechnol 29: 589–598
32. Wong SP, Harbottle RP (2013) Genetic modification of dividing cells using episomally maintained S/MAR DNA vectors. Mol Ther Nucleic acids 2: e115
33. Yu D, Jin C, Ramachandran M, Xu J, Nilsson B, Korsgren O, Le Blanc K, Uhrbom L, Forsberg-Nilsson K, Westermark B et al (2013) Adenovirus serotype 5 vectors with Tat-PTD modified hexon and serotype 35 fiber show greatly enhanced transduction capacity of primary cell cultures. PLoS ONE 8: e54952